TOKYO -- Japanese drugmaker Tsumura plans to capitalize on its partnership with China's Ping An Insurance Group to expand its herbal medicine sales in China to 10 billion yuan ($1.57 billion) by 2027.
"We aim to become the top brand of traditional Chinese medicine there," Tsumura President Terukazu Kato told reporters in Tokyo on Wednesday.
